Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care centre
Abstract Background Gastroenteropancreatic Neuroendocrine tumors (GEP-NET) are rare neoplasms with limited reported data from the Middle East. Our study aims to report the clinicopathological feature, treatment patterns, and survival outcomes of patients with GEP-NET from our part of the world. Meth...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-04-01
|
| Series: | BMC Endocrine Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12902-023-01326-1 |
| _version_ | 1797850038874931200 |
|---|---|
| author | Shouki Bazarbashi Mohamed Aseafan Tasnim Elgazzar Maha Alkhayat Abdulrahman Alghabban Marwa I. Abdelgawad Bader Alshamsan Aisha Alshibany Tusneem Elhassan Ali Aljubran Ahmed Alzahrani Hindi Alhindi Hussein Raef |
| author_facet | Shouki Bazarbashi Mohamed Aseafan Tasnim Elgazzar Maha Alkhayat Abdulrahman Alghabban Marwa I. Abdelgawad Bader Alshamsan Aisha Alshibany Tusneem Elhassan Ali Aljubran Ahmed Alzahrani Hindi Alhindi Hussein Raef |
| author_sort | Shouki Bazarbashi |
| collection | DOAJ |
| description | Abstract Background Gastroenteropancreatic Neuroendocrine tumors (GEP-NET) are rare neoplasms with limited reported data from the Middle East. Our study aims to report the clinicopathological feature, treatment patterns, and survival outcomes of patients with GEP-NET from our part of the world. Methods Medical records of patients diagnosed with GEP-NET between January 2011 and December 2016 at a single center in Saudi Arabia were reviewed retrospectively, and complete clinicopathological and treatment data were collected. Patients’ survival was estimated by the Kaplan–Meier method. Results A total of 72 patients were identified with a median age of 51 years (range 27–82) and male-to-female ratio of (1.1). The most common tumor location was the pancreas (29.1%), followed by small bowel (25%), stomach (12.5%), rectum (8.3%), colon (8.3%), and appendix (6.9%). Forty-one patients (57%) had well-differentiated grade (G)1, 21 (29%) had G2, and 4 (6%) had G3. In five patients, the pathology was neuroendocrine carcinoma and in one it could not be classified. 54.2% of the patients were metastatic at diagnosis. Forty-two patients underwent surgical resection as primary management while 26 underwent systemic therapy, three patients were put on active surveillance, and one was treated endoscopically with polypectomy. The 5-year overall survival and progression-free survivals were 77.2% and 49%, respectively, for the whole group. Patients with G1 and 2 disease, lower Ki-67 index, and surgically treated as primary management had significantly better survival outcomes. Conclusion Our study suggests that the most common tumor locations are similar to western reported data. However, there seems to be a higher incidence of metastatic disease at presentation than in the rest of the world. |
| first_indexed | 2024-04-09T18:53:55Z |
| format | Article |
| id | doaj.art-7dc2f539f59c4ff5b430a320d1a04bcb |
| institution | Directory Open Access Journal |
| issn | 1472-6823 |
| language | English |
| last_indexed | 2024-04-09T18:53:55Z |
| publishDate | 2023-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Endocrine Disorders |
| spelling | doaj.art-7dc2f539f59c4ff5b430a320d1a04bcb2023-04-09T11:18:51ZengBMCBMC Endocrine Disorders1472-68232023-04-012311710.1186/s12902-023-01326-1Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care centreShouki Bazarbashi0Mohamed Aseafan1Tasnim Elgazzar2Maha Alkhayat3Abdulrahman Alghabban4Marwa I. Abdelgawad5Bader Alshamsan6Aisha Alshibany7Tusneem Elhassan8Ali Aljubran9Ahmed Alzahrani10Hindi Alhindi11Hussein Raef12Section of Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research CenterSection of Medical Oncology, Department of Internal Medicine, Security Forces Hospital ProgramCollege of Medicine, Alfaisal UniversityCollege of Medicine, Alfaisal UniversitySection of Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research CenterSection of Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research CenterSection of Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research CenterSection of Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research CenterOncology Center, King Faisal Specialist Hospital and Research CenterSection of Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research CenterSection of Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research CenterDepartment of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research CenterSection of Endocrinology, Department of Internal Medicine, King Faisal Specialist Hospital and Research CenterAbstract Background Gastroenteropancreatic Neuroendocrine tumors (GEP-NET) are rare neoplasms with limited reported data from the Middle East. Our study aims to report the clinicopathological feature, treatment patterns, and survival outcomes of patients with GEP-NET from our part of the world. Methods Medical records of patients diagnosed with GEP-NET between January 2011 and December 2016 at a single center in Saudi Arabia were reviewed retrospectively, and complete clinicopathological and treatment data were collected. Patients’ survival was estimated by the Kaplan–Meier method. Results A total of 72 patients were identified with a median age of 51 years (range 27–82) and male-to-female ratio of (1.1). The most common tumor location was the pancreas (29.1%), followed by small bowel (25%), stomach (12.5%), rectum (8.3%), colon (8.3%), and appendix (6.9%). Forty-one patients (57%) had well-differentiated grade (G)1, 21 (29%) had G2, and 4 (6%) had G3. In five patients, the pathology was neuroendocrine carcinoma and in one it could not be classified. 54.2% of the patients were metastatic at diagnosis. Forty-two patients underwent surgical resection as primary management while 26 underwent systemic therapy, three patients were put on active surveillance, and one was treated endoscopically with polypectomy. The 5-year overall survival and progression-free survivals were 77.2% and 49%, respectively, for the whole group. Patients with G1 and 2 disease, lower Ki-67 index, and surgically treated as primary management had significantly better survival outcomes. Conclusion Our study suggests that the most common tumor locations are similar to western reported data. However, there seems to be a higher incidence of metastatic disease at presentation than in the rest of the world.https://doi.org/10.1186/s12902-023-01326-1Neuroendocrine tumorGastroenteropancreaticGEP-NETSurvival |
| spellingShingle | Shouki Bazarbashi Mohamed Aseafan Tasnim Elgazzar Maha Alkhayat Abdulrahman Alghabban Marwa I. Abdelgawad Bader Alshamsan Aisha Alshibany Tusneem Elhassan Ali Aljubran Ahmed Alzahrani Hindi Alhindi Hussein Raef Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care centre BMC Endocrine Disorders Neuroendocrine tumor Gastroenteropancreatic GEP-NET Survival |
| title | Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care centre |
| title_full | Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care centre |
| title_fullStr | Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care centre |
| title_full_unstemmed | Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care centre |
| title_short | Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care centre |
| title_sort | characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care centre |
| topic | Neuroendocrine tumor Gastroenteropancreatic GEP-NET Survival |
| url | https://doi.org/10.1186/s12902-023-01326-1 |
| work_keys_str_mv | AT shoukibazarbashi characteristicsandtreatmentresultsofpatientswithgastroenteropancreaticneuroendocrinetumorsinatertiarycarecentre AT mohamedaseafan characteristicsandtreatmentresultsofpatientswithgastroenteropancreaticneuroendocrinetumorsinatertiarycarecentre AT tasnimelgazzar characteristicsandtreatmentresultsofpatientswithgastroenteropancreaticneuroendocrinetumorsinatertiarycarecentre AT mahaalkhayat characteristicsandtreatmentresultsofpatientswithgastroenteropancreaticneuroendocrinetumorsinatertiarycarecentre AT abdulrahmanalghabban characteristicsandtreatmentresultsofpatientswithgastroenteropancreaticneuroendocrinetumorsinatertiarycarecentre AT marwaiabdelgawad characteristicsandtreatmentresultsofpatientswithgastroenteropancreaticneuroendocrinetumorsinatertiarycarecentre AT baderalshamsan characteristicsandtreatmentresultsofpatientswithgastroenteropancreaticneuroendocrinetumorsinatertiarycarecentre AT aishaalshibany characteristicsandtreatmentresultsofpatientswithgastroenteropancreaticneuroendocrinetumorsinatertiarycarecentre AT tusneemelhassan characteristicsandtreatmentresultsofpatientswithgastroenteropancreaticneuroendocrinetumorsinatertiarycarecentre AT alialjubran characteristicsandtreatmentresultsofpatientswithgastroenteropancreaticneuroendocrinetumorsinatertiarycarecentre AT ahmedalzahrani characteristicsandtreatmentresultsofpatientswithgastroenteropancreaticneuroendocrinetumorsinatertiarycarecentre AT hindialhindi characteristicsandtreatmentresultsofpatientswithgastroenteropancreaticneuroendocrinetumorsinatertiarycarecentre AT husseinraef characteristicsandtreatmentresultsofpatientswithgastroenteropancreaticneuroendocrinetumorsinatertiarycarecentre |